Human Albumin Baxalta 200 g/l Solution for Infusion Irland - engelsk - HPRA (Health Products Regulatory Authority)

human albumin baxalta 200 g/l solution for infusion

baxalta innovations gmbh - plasma protein containing at least 95% human albumin - solution for infusion - 200 gram(s)/litre - blood substitutes and plasma protein fractions; albumin - plasma substitutes and plasma protein fractions - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated, and use of a colloid is appropriate

Human Albumin Baxalta 50 g/l  Solution for Infusion Irland - engelsk - HPRA (Health Products Regulatory Authority)

human albumin baxalta 50 g/l solution for infusion

baxalta innovations gmbh - plasma protein containing at least 95% human albumin - solution for infusion - 50 gram(s)/litre - blood substitutes and plasma protein fractions; albumin - plasma substitutes and plasma protein fractions - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated, and use of a colloid is appropriate.

ALBUREX - 5 SOLUTION Canada - engelsk - Health Canada

alburex - 5 solution

csl behring canada inc - albumin (human) - solution - 5% - albumin (human) 5% - blood derivatives

ALBUREX - 25 SOLUTION Canada - engelsk - Health Canada

alburex - 25 solution

csl behring canada inc - albumin (human) - solution - 25% - albumin (human) 25% - blood derivatives

OCTALBIN 25% SOLUTION Canada - engelsk - Health Canada

octalbin 25% solution

octapharma pharmazeutika produktionsges m b h - albumin (human) - solution - 25% - albumin (human) 25% - blood derivatives

OCTALBIN 5% SOLUTION Canada - engelsk - Health Canada

octalbin 5% solution

octapharma pharmazeutika produktionsges m b h - albumin (human) - solution - 5% - albumin (human) 5% - blood derivatives

BUMINATE 5% SOLUTION Canada - engelsk - Health Canada

buminate 5% solution

baxter healthcare corporation - albumin (human) - solution - 5% - albumin (human) 5% - blood derivatives

BUMINATE 25% SOLUTION Canada - engelsk - Health Canada

buminate 25% solution

baxter healthcare corporation - albumin (human) - solution - 25% - albumin (human) 25% - blood derivatives

HUMAN ALBUMIN GRIFOLS (albumin- human solution USA - engelsk - NLM (National Library of Medicine)

human albumin grifols (albumin- human solution

grifols usa, llc - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 12.5 g in 50 ml - for restoration and maintenance of circulating blood volume where hypovolemia is demonstrated and colloid use is appropriate. when hypovolemia is long standing and hypoalbuminemia exists accompanied by adequate hydration or edema, 20-25% albumin solutions should be used.1,2,3 acute liver failure is a special situation in which both hypovolemia and hypoalbuminemia can be present. human albumin grifols® 25% can be used in such cases.1 human albumin grifols 25% may be of value in the treatment of shock or hypotension in renal dialysis patients.1 preoperative dilution of blood using albumin and crystalloid can be used in cardiopulmonary bypass procedures. albumin also may be used in the priming fluid.4,5,6 human albumin grifols 25% may be used to treat peripheral edema in patients with acute nephrosis who are refractory to cyclophosphamide, corticosteroid therapy or diuretics.1,2,7 human albumin grifols 25% may be indicated for subjects with hypoalbuminemia who are critically ill and/or actively bleeding. when

KEDBUMIN (albumin- human injection, solution USA - engelsk - NLM (National Library of Medicine)

kedbumin (albumin- human injection, solution

kedrion s.p.a - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin (human) 12.5 g in 50 ml - for restoration and maintenance of circulating blood volume where volume deficiency is demonstrated and colloid use is appropriate. kedbumin® is indicated for severe albumin deficiency caused by illness or active bleeding. when albumin deficiency results from excessive protein loss, the effect of albumin administration will be temporary unless the underlying disorder is reversed. kedbumin® is indicated for maintenance of cardiovascular function following the removal of large volumes of ascitic fluid due to cirrhosis [1, 2]. kedbumin® is indicated as a plasma expander in the fluid management of severe forms of ovarian hyperstimulation syndrome (ohss) [3, 4]. kedbumin® is indicated in conjunction with diuretics to correct fluid volume overload associated with ards [5]. kedbumin® is indicated after > 24 hours post burn in patients experiencing severe albumin depletion in order to favor edema re-absorption [6]. kedbumin® is indicated in patients undergoing long term dialysis or for those patients who are fl